StockWatch
·

Adaptive Biotechnologies Corp Q3 FY26 Results

ADPTQ3 FY26 Results
Filing
MetricValue ($ M)Q3 FY25
Revenue83.9010.7%
Total Income83.9010.7%
Expenditure84.360.8%
PBT—
Net Profit2.8869.8%
OPM-0.55%11.49pp
NPM3.43%6.73pp
EPS0.0266.7%
View full financials

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

05 Nov 2026 · 5 Nov, 2:53 am

Summary

Adaptive Biotechnologies reported third quarter 2026 financial results, achieving total company profitability ahead of expectations with adjusted EBITDA of $14.3 million. While total revenue decreased 11% year-over-year to $83.9 million, excluding the Genentech Agreement, revenue increased by 39%. The company saw significant growth in its MRD business, with MRD revenue up 28% year-over-year to $72.6 million and clonoSEQ® tests increasing by 46%. Management raised the full-year 2026 MRD revenue guidance to $276 million-$286 million, reflecting strong momentum and the increasing need for MRD testing.

Key Highlights

  1. 1

    Adaptive Biotechnologies reported total company profitability ahead of expectations in Q3 2026, with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million.

  2. 2

    MRD revenue increased 28% year-over-year to $72.6 million in the third quarter of 2026, and 44% excluding milestones.

  3. 3

    The company delivered 39,587 clonoSEQ® tests in Q3 2026, representing a 46% increase compared to the third quarter of 2025.

  4. 4

    Total revenue for the third quarter of 2026 was $83.9 million, a decrease of 11% from the prior year, but revenue increased 39% excluding the Genentech Agreement.

  5. 5

    Adaptive Biotechnologies raised its full year 2026 MRD revenue guidance to a range of $276 million to $286 million, indicating 30% to 35% annual growth.

  6. 6

    Net income for the third quarter of 2026 was $2.8 million, compared to $9.5 million in the same period of 2025.

Management Comments

C

Chad Robins

Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.

Informational and educational content only. Not investment advice.